Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBMGNASDAQ:IOVANASDAQ:LENZNASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBMGCellular Biomedicine Group$19.68$11.48▼$19.75$384.69M1.35129,776 shs8,375 shsIOVAIovance Biotherapeutics$2.24-3.0%$2.55$1.64▼$12.51$748.01M0.868.92 million shs8.78 million shsLENZLENZ Therapeutics$29.00-2.0%$26.94$16.28▼$38.93$816.23M0.42190,874 shs156,488 shsNVAXNovavax$6.94-2.9%$6.71$5.01▼$17.81$1.12B2.816.53 million shs5.16 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBMGCellular Biomedicine Group0.00%0.00%0.00%0.00%0.00%IOVAIovance Biotherapeutics0.00%+9.27%+27.27%-37.60%-73.74%LENZLENZ Therapeutics0.00%-9.26%+6.07%+13.95%+55.00%NVAXNovavax0.00%-6.85%+10.33%-13.14%-56.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBMGCellular Biomedicine GroupN/AN/AN/AN/AN/AN/AN/AN/AIOVAIovance Biotherapeutics4.6367 of 5 stars4.31.00.04.22.24.21.3LENZLENZ Therapeutics1.4995 of 5 stars3.61.00.00.02.20.80.0NVAXNovavax3.8533 of 5 stars3.32.00.04.72.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBMGCellular Biomedicine Group 0.00N/AN/AN/AIOVAIovance Biotherapeutics 2.50Moderate Buy$13.30493.75% UpsideLENZLENZ Therapeutics 3.17Buy$46.6060.69% UpsideNVAXNovavax 2.50Moderate Buy$19.20176.66% UpsideCurrent Analyst Ratings BreakdownLatest CBMG, NVAX, IOVA, and LENZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/16/2025IOVAIovance BiotherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$17.00 ➝ $2.005/12/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $8.005/12/2025IOVAIovance BiotherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $10.005/12/2025IOVAIovance BiotherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/12/2025IOVAIovance BiotherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/9/2025IOVAIovance BiotherapeuticsBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025IOVAIovance BiotherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform5/9/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $25.005/9/2025IOVAIovance BiotherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/9/2025IOVAIovance BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $20.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBMGCellular Biomedicine Group$340K0.00N/AN/A$2.89 per share0.00IOVAIovance Biotherapeutics$212.68M3.52N/AN/A$2.28 per share0.98LENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/ANVAXNovavax$1.21B0.93N/AN/A($6.04) per share-1.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBMGCellular Biomedicine Group-$49.98MN/AN/AN/AN/AN/A-144.80%-61.68%N/AIOVAIovance Biotherapeutics-$444.04M-$1.24N/AN/AN/A-451.25%-58.43%-45.48%8/6/2025 (Estimated)LENZLENZ Therapeutics-$124.65M-$1.77N/AN/AN/AN/A-58.48%-55.50%8/13/2025 (Estimated)NVAXNovavax-$545.06M$2.65N/A86.752.85-32.18%N/A-17.05%8/14/2025 (Estimated)Latest CBMG, NVAX, IOVA, and LENZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025IOVAIovance Biotherapeutics-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A3/19/2025Q4 2024LENZLENZ Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBMGCellular Biomedicine GroupN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBMGCellular Biomedicine GroupN/A0.470.47IOVAIovance BiotherapeuticsN/A4.223.90LENZLENZ TherapeuticsN/A28.6328.63NVAXNovavaxN/A0.930.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBMGCellular Biomedicine Group21.98%IOVAIovance Biotherapeutics77.03%LENZLENZ Therapeutics54.32%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipCBMGCellular Biomedicine Group8.50%IOVAIovance Biotherapeutics10.30%LENZLENZ Therapeutics6.90%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBMGCellular Biomedicine Group21719.48 millionN/AOptionableIOVAIovance Biotherapeutics500333.93 million267.90 millionOptionableLENZLENZ Therapeutics11028.15 million16.94 millionN/ANVAXNovavax1,990161.97 million158.58 millionOptionableCBMG, NVAX, IOVA, and LENZ HeadlinesRecent News About These CompaniesAnalysts Conflicted on These Healthcare Names: Novavax (NVAX) and Intuitive Surgical (ISRG)June 14 at 3:02 AM | theglobeandmail.comNovavax: New Vaccine, Same Old Story - Still A SellJune 13 at 11:52 AM | seekingalpha.comNovavax, Inc. (NASDAQ:NVAX) Shares Sold by SG Americas Securities LLCJune 13 at 4:21 AM | marketbeat.comNovavax's COVID-Flu Combo Shot Shows Strong Immune ResponseJune 12 at 9:16 AM | zacks.comNovavax's COVID-flu combo vaccine shows strong immune response in trialJune 12 at 8:10 AM | msn.comNovavax preps late-stage trial as COVID-flu combo vaccine matches rivalsJune 12 at 8:10 AM | thepharmaletter.comNovavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptJune 11, 2025 | seekingalpha.comNovavax’s COVID-flu combo vaccine shows strong immune responseJune 11, 2025 | msn.comTesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fallJune 11, 2025 | investing.comNovavax posts immune data to back COVID-flu combo shot and standalone flu shotJune 11, 2025 | msn.comNovavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine CandidatesJune 11, 2025 | finance.yahoo.comNovavax’s Covid-Flu Combo, Standalone Flu Vaccines Demonstrate Robust Immune Response In Late-Stage Trial: Retail Says It’s ‘A Very Good Sign’June 11, 2025 | msn.comNovavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 TrialJune 11, 2025 | benzinga.comNovavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy?June 11, 2025 | zacks.comNovavax Stock (NVAX) Gets a Boost from ‘Robust Immune Responses’June 11, 2025 | tipranks.comNovavax Reports Promising Phase 3 Vaccine Trial ResultsJune 11, 2025 | tipranks.comNovavax's COVID-flu combo and standalone flu shots improve immunity in late-stage studyJune 11, 2025 | reuters.comNovavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 TrialJune 11, 2025 | prnewswire.comWhy Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.June 10, 2025 | barrons.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.16 Million Position in Novavax, Inc. (NASDAQ:NVAX)June 7, 2025 | marketbeat.comNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItJune 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBMG, NVAX, IOVA, and LENZ Company DescriptionsCellular Biomedicine Group NASDAQ:CBMGCellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Iovance Biotherapeutics NASDAQ:IOVA$2.24 -0.07 (-3.03%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.24 -0.01 (-0.22%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.LENZ Therapeutics NASDAQ:LENZ$29.00 -0.58 (-1.96%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$29.08 +0.08 (+0.28%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Novavax NASDAQ:NVAX$6.94 -0.21 (-2.94%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$7.02 +0.07 (+1.08%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.